371 related articles for article (PubMed ID: 25850931)
1. Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.
Sutton EJ; Oh JH; Dashevsky BZ; Veeraraghavan H; Apte AP; Thakur SB; Deasy JO; Morris EA
J Magn Reson Imaging; 2015 Nov; 42(5):1398-406. PubMed ID: 25850931
[TBL] [Abstract][Full Text] [Related]
2. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
3. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
Li H; Zhu Y; Burnside ES; Drukker K; Hoadley KA; Fan C; Conzen SD; Whitman GJ; Sutton EJ; Net JM; Ganott M; Huang E; Morris EA; Perou CM; Ji Y; Giger ML
Radiology; 2016 Nov; 281(2):382-391. PubMed ID: 27144536
[TBL] [Abstract][Full Text] [Related]
4. An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.
Felts JL; Zhu J; Han B; Smith SJ; Truica CI
Breast J; 2017 Nov; 23(6):677-686. PubMed ID: 28097781
[TBL] [Abstract][Full Text] [Related]
5. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
Auerbach J; Kim M; Fineberg S
Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
[TBL] [Abstract][Full Text] [Related]
6. Is there different correlation with prognostic factors between "non-mass" and "mass" type invasive ductal breast cancers?
Jiang L; Zhou Y; Wang Z; Lu X; Chen M; Zhou C
Eur J Radiol; 2013 Sep; 82(9):1404-9. PubMed ID: 23540946
[TBL] [Abstract][Full Text] [Related]
7. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer molecular subtype classifier that incorporates MRI features.
Sutton EJ; Dashevsky BZ; Oh JH; Veeraraghavan H; Apte AP; Thakur SB; Morris EA; Deasy JO
J Magn Reson Imaging; 2016 Jul; 44(1):122-9. PubMed ID: 26756416
[TBL] [Abstract][Full Text] [Related]
9. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
[TBL] [Abstract][Full Text] [Related]
11. Convolutional Neural Network Using a Breast MRI Tumor Dataset Can Predict Oncotype Dx Recurrence Score.
Ha R; Chang P; Mutasa S; Karcich J; Goodman S; Blum E; Kalinsky K; Liu MZ; Jambawalikar S
J Magn Reson Imaging; 2019 Feb; 49(2):518-524. PubMed ID: 30129697
[TBL] [Abstract][Full Text] [Related]
12. Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes.
Bae MS; Seo M; Kim KG; Park IA; Moon WK
Acta Radiol; 2015 Mar; 56(3):269-75. PubMed ID: 24558165
[TBL] [Abstract][Full Text] [Related]
13. Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer.
Kim HJ; Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
Clin Imaging; 2021 Jul; 75():131-137. PubMed ID: 33548871
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.
Wilson PC; Chagpar AB; Cicek AF; Bossuyt V; Buza N; Mougalian S; Killelea BK; Patel N; Harigopal M
Breast J; 2018 Nov; 24(6):976-980. PubMed ID: 30230117
[TBL] [Abstract][Full Text] [Related]
15. Qualitative Radiogenomics: Association between Oncotype DX Test Recurrence Score and BI-RADS Mammographic and Breast MR Imaging Features.
Woodard GA; Ray KM; Joe BN; Price ER
Radiology; 2018 Jan; 286(1):60-70. PubMed ID: 28885890
[TBL] [Abstract][Full Text] [Related]
16. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
Allison KH; Kandalaft PL; Sitlani CM; Dintzis SM; Gown AM
Breast Cancer Res Treat; 2012 Jan; 131(2):413-24. PubMed ID: 21369717
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Low versus High Recurrence Scores in Estrogen Receptor-Positive, Lymph Node-Negative Invasive Breast Cancer on the Basis of Radiologic-Pathologic Features: Comparison with Oncotype DX Test Recurrence Scores.
Dialani V; Gaur S; Mehta TS; Venkataraman S; Fein-Zachary V; Phillips J; Brook A; Slanetz PJ
Radiology; 2016 Aug; 280(2):370-8. PubMed ID: 26937802
[TBL] [Abstract][Full Text] [Related]
18. Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).
Hou Y; Tozbikian G; Zynger DL; Li Z
Am J Clin Pathol; 2017 Jun; 147(6):541-548. PubMed ID: 28449064
[TBL] [Abstract][Full Text] [Related]
19. Radiomics signature on 3T dynamic contrast-enhanced magnetic resonance imaging for estrogen receptor-positive invasive breast cancers: Preliminary results for correlation with Oncotype DX recurrence scores.
Nam KJ; Park H; Ko ES; Lim Y; Cho HH; Lee JE
Medicine (Baltimore); 2019 Jun; 98(23):e15871. PubMed ID: 31169691
[TBL] [Abstract][Full Text] [Related]
20. MRI findings of cancers preoperatively diagnosed as pure DCIS at core needle biopsy.
Huang YT; Cheung YC; Lo YF; Ueng SH; Kuo WL; Chen SC
Acta Radiol; 2011 Dec; 52(10):1064-8. PubMed ID: 21969708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]